One year of treatment with saroglitazar, Zydus Therapeutics’ experimental oral candidate, outperformed a placebo at normalizing markers of liver injury in people with primary biliary cholangitis (PBC), according to top-line data from a Phase 2b/3 clinical trial. The new findings mean that the Phase 2b/3 EPICS-III study (NCT05133336) — which included adults who did not […] The post New trial data show saroglitazar works to ease liver damage in PBC appeared first on Liver Disease News.
